J. Gokemeijer

发表

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

A. Tolcher, K. Papadopoulos, A. Patnaik, 2011, Clinical Cancer Research.

Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two.

Y. Chen, D. Lipovšek, J. Gokemeijer, 2005, Protein engineering, design & selection : PEDS.

Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2

Martin C. Wright, R. Kerbel, R. Mamluk, 2010, mAbs.

Altering drug tolerance of surface plasmon resonance assays for the detection of anti-drug antibodies.

J. Gokemeijer, A. Bush, Aaron Martin, 2013, Analytical biochemistry.

Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression

Martin C. Wright, Joonyoung Kim, W. Hayes, 2017, The Journal of Nuclear Medicine.

T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

A. D. De Groot, J. Gokemeijer, V. Jawa, 2020, Frontiers in Immunology.

A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor

Martin C. Wright, A. Yamniuk, M. Doyle, 2011, mAbs.

Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies

Guodong Chen, Mohammed Jemal, Russell Weiner, 2011, Analytical and Bioanalytical Chemistry.

A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins

Maciej J. Swat, Craig J. Thalhauser, B. Small, 2019, CPT: pharmacometrics & systems pharmacology.

How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry Perspective

J. Gokemeijer, V. Jawa, S. Mitra-Kaushik, 2017, The AAPS Journal.

Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro.

Lin Sun, Veena Warikoo, Lin Sun, 2006, Chemistry & biology.

Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors.

A. Korman, A. Nagrial, L. Siu, 2017 .

Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug Development

K. Lamberth, J. Gokemeijer, Yvonne Ying-Ya Wen, 2023, The AAPS Journal.

Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective

J. Gokemeijer, H. Mody, V. Jawa, 2023, Clinical pharmacology and therapeutics.

An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR‐T and TCR‐T Cellular Therapies Development

J. Gokemeijer, V. Jawa, Swati Gupta, 2023, Clinical pharmacology and therapeutics.